Home
overview

SMi proudly presents the 2nd annual conference on Cancer Vaccines. This year’s event aims to focus on innovation and novel strategies within the field, the regulatory environment, and the future direction of cancer vaccines; as well as offering current preclinical and clinical outlook, data, and case studies.

As cancer is still one of the greatest causes of human mortality it is a very attractive target for vaccination. Despite a dramatic increase in research within cancer vaccines in the last decade, there is still a need for more effective therapies to maximise cancer survival rates. Novel strategies for target selection, vaccine design, immunostimulatory therapies, and other biologics are constantly being developed and improved.

The conference, now in its 2nd year, annual Cancer Vaccine conference will examine not only the current clinical data but also the new innovations within the field. This informative event will draw from expert opinions, groundbreaking data, and regulatory factors to look to the future and assess where the field is advancing. This really is a unique event not to be missed.

  • Explore innovative and novel strategies, approaches, and vaccines within the field.
  • Discover future trends, the direction of the field, and combination strategies in both preclinical and clinical situations.
  • Evaluate the regulatory environment and the subsequent impact on cancer vaccine development.
  • Consider current trial data, clinical developments, and successful therapeutic vaccines.
  • Learn from the successes, failures, and challenges of experts in the field and apply to optimise vaccine development.

 

Chief Executives, Chief Scientific Officers, Vice Presidents, Heads, Directors, Principal Scientists, Project Leaders, and Managers in the following areas:

 • Oncology
• Formulation Development
• Drug delivery
• Immunology
• Antibody engineering
• Immunoassay development
• Structural vaccinology
• Immunotherapeutics
• Translational Medicine  

 • Tumor Immunology & Biology
• Discovery Chemistry
• Molecular Medicine
• Immunogenetics
• Molecular Discovery Research
• Molecular Microbiology and Chemistry
• Regulatory Affairs
• Business Development
• Genomics
 

 

Activartis Biotech GmbH; Boehringer Ingelheim Pharma Gmbh; Cancer Research Technology Ltd; Cancer Research UK; Cancer Vaccines Ltd; Castrol Austria Ges Mbh; Cure Vac; CytoVac; DanDrit Biotech; Fanelli Haag & Kilger PLLC; Glaxosmithkline Biologicals; Helsinn Healthcare SA; Immudex; Immunocore; Imperial College London; Imperial Innovations; Indena SpA; Innsbruck Medical University; INSERM; Instituto Nazionale Tumori; Institut Pasteur; Institut Universitaire D'hematologie; Interlab Central Lab Services-Worldwide Gmb H; Istituto Nazionale Tumori; JPT Peptide Technologies; Kings College London; LabCorp Clinical Trials; Merck KGaA; Merck Serono; N.N. Blokhin Cancer Research Center; NHS Trust; Novartis Vaccines and Diagnostics, Inc.; Pan Therapeutics; Pharmaceutical Company; Thomson Reuters; TriMod Therapeutics; UCL Cancer Institute; Universität Heidelberg; University of Birmingham; University of Malta; University of Nottingham; University Of Southampton; University of Tuebingen Medical School.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Oliver Wilbert

Oliver Wilbert, Senior Director Immunotherapies, Merck KGaA

9:10 Advances & Challenges in the Development of Novel Cancer Immunotherapies

Oliver Wilbert

Oliver Wilbert, Senior Director Immunotherapies, Merck KGaA

9:50 An insight on the key results of START, a phase III trial of L-BLP25 (tecemotide) antigen specific immunotherapy

Sonia Quaratino

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

10:30 Morning Coffee

10:50 Accurate and Reliable Immune Monitoring in Cancer Vaccine Development

Søren Jakobsen

Søren Jakobsen, Senior Scientist, Immudex

Proficiency Panel Services

2-dimensional and multiplex MHC multimer analysis
in situ staining of antigen-specific T cells

11:30 Developing antibodies to stimulate anti-cancer immunity

Martin Glennie

Martin Glennie, Professor of Immunochemistry, University Of Southampton

Discuss the nature of anti-cancer immunity and the ability of the immune system to recognise most types of cancer

Explore how antibodies recognising key members of the TNFR superfamily can stimulate T-cell responses against cancer
Show that these immuno stimulating antibodies need to engage Fc receptors in the host to provide sufficient crosslinking of the various TNFRs
Discuss how antibody engineering will be used to optimise crosslinking activity in vivo

12:10 Inducible “Remote Control” Activation of Dendritic Cells

Kevin Slawin

Kevin Slawin, Executive Chairman & CMO, Bellicum Pharmaceuticals

Describe “chemical induction of dimerization (CID)” technology

Describe the use of a CID-controllable CD40-MyD88 activation switch to activate dendritic cells in the correct context
Review results of a Phase I trial of BPX-101, a PSMA-targeted prostate cancer DC vaccine that incorporated a CID-controllable CD40 activation switch

12:50 Networking Lunch

14:10 Improving the clinical efficacy of human cancer vaccines by targeting immune suppression in tumours

Pierre van der Bruggen

Pierre van der Bruggen, Group Leader, Ludwig Institute for Cancer Research

Clinical efficacy of therapeutic cancer vaccines without massive anti-vaccine T cell responses
Current challenges for the clinical efficacy of therapeutic cancer vaccines
Immunosuppression and the resulting impact on cancer vaccines
Soluble galectin antagonists may improve therapeutic vaccine success
 

14:50 Clinical and preclinical aspects of MVA-MUC1-based cancer immunotherapy in NSCLC

Ronald Rooke

Ronald Rooke, Head of Immunopharmacology, Transgene SA

Background

Clinical data

Biomarker identification

Preclinical modelization

15:30 Identification of Biomarkers Predictive of Clinical and Immunological Efficacy in Cancer Patients Treated with TroVax

Richard Harrop

Richard Harrop, Head of Clinical Analysis, Oxford BioMedica (U K) Limited

Cancer vaccines may have a delayed therapeutic effect, thus an early efficacy marker would be valuable

Few immunotherapy compounds have demonstrated a clear link between the predicted mode of action of the product and clinical benefit
Case study data of phase III trial of TroVax in renal cancer patients 
Development of a biomarker using pre-treatment factors which  are readily measured in patients and application to independent dataset comprising patients with renal, colorectal and prostate cancer

16:10 Chairman’s Closing Remarks

16:15 Afternoon Tea

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sonia Quaratino

Sonia Quaratino, Senior Medical Director and Immunology Advisor, Merck Serono

9:10 Treating Cancer in the Age of Modern Immunotherapy

Ravi Madan

Ravi Madan, Assistant Clinical Investigator, National Cancer Institute

9:50 Manipulating Tumour Immunogenicity in vivo: New Tools for Old Targets

Mark Cobbold

Mark Cobbold, Senior Clinical Research Fellow, University of Birmingham

The talk will describe a new technology to alter the immunogenicity of a tumour in vivo.
Tumour immunogenicity can be manipulated by the delivery of antigens at the tumour site.
The engagement of pre-existing immunity with tumours provides novel mechanism for immunotherapy
Analogous to effective conjugate vaccines
 

10:30 Morning Coffee

10:50 MHC-Peptide Tetramers: Useful tools for optimizing TCR avidity towards tumor antigen peptides in retrovirally transduced T lymphocytes and increasing tumor killing

Shao-An Xue

Shao-An Xue, Senior Lecturer, Research Department of Immunology, MBL International Corporation

Adoptive immunotherapy using TCR gene modified T cells, has not been very successful
TCR constructs, were retrovirally transferred in autologous human T lymphocytes, and tested for cytokine production and tumor killing
T lymphocytes transduced with WT1-TCRs constructs showing a higher tetramer staining had higher production and activity both in vitro and in vivo in mice
MHC- tumor peptide tetramers can be used to select TCR-transduced T lymphocytes with higher tumoricidal activity
 

11:30 Immunological biomarkers predicting survival in late-stage melanoma patients

Graham Pawelec

Graham Pawelec, Professor of Experimental Immunology, University Of Tuebingen

The M category, the presence of NY-ESO-1-reactive T cells and the frequency of CD14+HLA-DR-/low MDSCs in the peripheral blood are associated with survival in late-stage melanoma patients 

Presence of NY-ESO-1-reactive T cells and the M category independently contribute to prognosis of unresectable stage IV melanoma patients
Frequency of MDSCs and the M category independently contribute to prognosis of unresectable stage IV melanoma patients
Frequency of Tregs and presence of Melan A-reactive T cells do not contribute to prognosis of unresectable stage IV melanoma patients

12:10 Networking Lunch

13:30 HPV vaccination programme in Scotland

Kevin Pollock

Kevin Pollock, Senior Epidemiologist, NHS National Services Scotland

High uptake of HPV vaccine in routine cohort(>90%) and catch-up cohort (>65%)
Reduction of high-risk HPV in catch-up cohort
Evaluation of vaccine on cervical cancer precursors (CIN1,2 and 3)
HOPScotch study - HPV oral prevalence in Scotland

14:10 Flipper DNA Vaccine Adjuvant induces immune responses and extends life-span in Mouse Models of acute promyelocytic leukemia and myelodysplastic syndrome

Rose-Ann Padua

Rose-Ann Padua, Research Director, INSERM

DNA vaccination with all-trans retinoic acid induces long term remissions with immune responses in acute promyelocytic leukemia (APL) mice

Novel construct, Flipper, containing additional GC-rich sequences and coding for unique immunogenic peptides was cloned

In normal mice Flipper increased IFNg producing cells in Elispot assays, memory T-cells and MYD88 transcripts

In PML-RARa-mediated APL and NRASD12.BCL-2-mediated MDS mice, extended life-span was observed with immune responses measured and reduction of minimal residual for APL and protein modifications of RAS signaling by NanoPro

 

14:50 Afternoon Tea

15:10 Advances in cellular immunotherapies for cancer

John Maudsley

John Maudsley, CEO, Cancer Vaccines Ltd

Recent advances

Advantages of allogeneic
Markers of safety and efficacy
Future directions

15:50 Global overview of cancer vaccines: Are we moving forward?

Alex Kudrin

Alex Kudrin, Medical Assessor, Biologicals Licensing, MHRA

Why we need cancer immunotherapy and why there is continued interest from the industry and academic communities.
Who are the key players and what is the landscape of the field: products in phase II-III studies.
What is believed to be the new paradigm in cancer immunotherapy. 
Challenges in translating non-clinical data into human models.
Clinical trial design and conduct from both the FDA and EMA perspective. 
The implication of new immunotherapies on health care and reimbursement.

16:30 Chairman’s Closing Remarks and Close of Day Two

+

FEATURED SPEAKERS

Alex Kudrin

Alex Kudrin

Medical Assessor, Biologicals Licensing, MHRA
Graham Pawelec

Graham Pawelec

Professor of Experimental Immunology, University Of Tuebingen
Martin Glennie

Martin Glennie

Professor of Immunochemistry, University Of Southampton
Oliver Wilbert

Oliver Wilbert

Senior Director Immunotherapies, Merck KGaA
Pierre van der Bruggen

Pierre van der Bruggen

Group Leader, Ludwig Institute for Cancer Research
Rose-Ann Padua

Rose-Ann Padua

Research Director, INSERM
Sonia Quaratino

Sonia Quaratino

Senior Medical Director and Immunology Advisor, Merck Serono

Alex Kudrin

Medical Assessor, Biologicals Licensing, MHRA
Alex Kudrin

Graham Pawelec

Professor of Experimental Immunology, University Of Tuebingen
Graham Pawelec

John Maudsley

CEO, Cancer Vaccines Ltd
John Maudsley

Kevin Pollock

Senior Epidemiologist, NHS National Services Scotland
Kevin Pollock

Kevin Slawin

Executive Chairman & CMO, Bellicum Pharmaceuticals
Kevin Slawin

Liselotte Brix

COO, Immudex
Liselotte Brix

Mark Cobbold

Senior Clinical Research Fellow, University of Birmingham
Mark Cobbold

Martin Glennie

Professor of Immunochemistry, University Of Southampton
Martin Glennie

Oliver Wilbert

Senior Director Immunotherapies, Merck KGaA
Oliver Wilbert

Pierre van der Bruggen

Group Leader, Ludwig Institute for Cancer Research
Pierre van der Bruggen

Ravi Madan

Assistant Clinical Investigator, National Cancer Institute
Ravi Madan

Richard Harrop

Head of Clinical Analysis, Oxford BioMedica (U K) Limited
Richard Harrop

Ronald Rooke

Head of Immunopharmacology, Transgene SA
Ronald Rooke

Rose-Ann Padua

Research Director, INSERM
Rose-Ann Padua

Shao-An Xue

Senior Lecturer, Research Department of Immunology, MBL International Corporation
Shao-An Xue

Sonia Quaratino

Senior Medical Director and Immunology Advisor, Merck Serono
Sonia Quaratino

Søren Jakobsen

Senior Scientist, Immudex
Søren Jakobsen

Workshops

Combination Therapies with Immunotherapeutics
Workshop

Combination Therapies with Immunotherapeutics

Holiday Inn Regents Park
17th September 2013
London, United Kingdom

Holiday Inn Regents Park

Carburton Street
London W1W 5EE
United Kingdom

Holiday Inn Regents Park

Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.